Terms: = Breast cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
264 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and ret Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract] [Full Text] [Related]
3. [A Case Report of Multiple Endocrine Neoplasia Type 2A(men2a)Diagnosed with Medullary Thyroid Carcinoma].
Morikawa N; Yoshitomi S; Shimabara M; Tatara N; Hara K; Ikeda E; Tsuji H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1780-1782. PubMed ID: 38303205
[TBL] [Abstract] [Full Text] [Related]
4. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes.
Bull CJ; Hazelwood E; Legge DN; Corbin LJ; Richardson TG; Lee M; Yarmolinsky J; Smith-Byrne K; Hughes DA; Johansson M; Peters U; Berndt SI; Brenner H; Burnett-Hartman A; Cheng I; Kweon SS; Le Marchand L; Li L; Newcomb PA; Pearlman R; McConnachie A; Welsh P; Taylor R; Lean MEJ; Sattar N; Murphy N; Gunter MJ; Timpson NJ; Vincent EE
EBioMedicine; 2024 Feb; 100():104977. PubMed ID: 38290287
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of pralsetinib in Chinese advanced ret-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
6. A case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma.
Tanaka A; Okita R; Morishige T; Okada M; Inokawa H; Hirazawa K; Kameyama K; Ikeda A; Ikeda E
Thorac Cancer; 2024 Feb; 15(4):353-357. PubMed ID: 38131508
[TBL] [Abstract] [Full Text] [Related]
7. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
8. Amplification of Wild-Type
Gandhi MM; Ricciuti B; Harada G; Repetto M; Gildenberg MS; Singh A; Li YY; Gagné A; Wang X; Aizer A; Fitzgerald K; Nishino M; Alessi J; Pecci F; Di Federico A; Fisch A; Drilon A; Nardi V; Sholl L; Awad MM; Rotow J
JCO Precis Oncol; 2023 Sep; 7():e2300295. PubMed ID: 37972337
[TBL] [Abstract] [Full Text] [Related]
9. retooling the ret Inhibitor Pralsetinib for ESR1 Fusion-Positive breast cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract] [Full Text] [Related]
10. European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
Normanno N; Machado JC; Pescarmona E; Buglioni S; Navarro L; Esposito Abate R; Ferro A; Mensink R; Lambiase M; Lespinet-Fabre V; Calgua B; Jermann PM; Ilié M; Hofman P
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762091
[TBL] [Abstract] [Full Text] [Related]
11. ECL resonance energy transfer-regulated "off-on" mode biosensor for the detection of miRNA-150-5p in triple negative breast cancer.
Zhong W; Liang Z; Zhao H; Wang P; Li Z; Shi J; Ma Q
Biosens Bioelectron; 2023 Nov; 240():115663. PubMed ID: 37678060
[TBL] [Abstract] [Full Text] [Related]
12. Targeting the ret tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA; Basilaia M; Kim W; Getz T; Gustafson JL; Zage PE
Biochem Pharmacol; 2023 Oct; 216():115751. PubMed ID: 37595672
[TBL] [Abstract] [Full Text] [Related]
13. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive breast cancers for Targeted Treatment.
Kim BJ; Zheng ZY; Lei JT; Holt MV; Chen A; Peng J; Fandino D; Singh P; Kennedy H; Dou Y; Chica-Parrado MDR; Bikorimana E; Ye D; Wang Y; Hanker AB; Mohamed N; Hilsenbeck SG; Lim B; Asirvatham JR; Sreekumar A; Zhang B; Miles G; Anurag M; Ellis MJ; Chang EC
Cancer Res Commun; 2023 Jul; 3(7):1366-1377. PubMed ID: 37501682
[TBL] [Abstract] [Full Text] [Related]
14. Mutational profiling of Chinese patients with thyroid cancer.
Du Y; Zhang S; Zhang G; Hu J; Zhao L; Xiong Y; Shen L; Chen R; Ye K; Xu Y
Front Endocrinol (Lausanne); 2023; 14():1156999. PubMed ID: 37465126
[TBL] [Abstract] [Full Text] [Related]
15. Ponatinib: An update on its drug targets, therapeutic potential and safety.
Gao Y; Ding Y; Tai XR; Zhang C; Wang D
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188949. PubMed ID: 37399979
[TBL] [Abstract] [Full Text] [Related]
16. FDA Approval Summary: Selpercatinib for the Treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
17. Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study.
Caru M; Abdullah S; Qiu L; Kanski B; Gordon B; Truica CI; Vasakar M; Doerksen S; Schmitz KH
Breast Cancer Res Treat; 2023 Jul; 200(2):265-270. PubMed ID: 37227610
[TBL] [Abstract] [Full Text] [Related]
18. Highly sensitive droplet digital PCR for detection of ret fusion in papillary thyroid cancer.
Chen M; Xue J; Sang Y; Jiang W; He W; Hong S; Lv W; Xiao H; Liu R
BMC Cancer; 2023 Apr; 23(1):363. PubMed ID: 37081420
[TBL] [Abstract] [Full Text] [Related]
19. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven breast cancer.
Gou X; Kim BJ; Anurag M; Lei JT; Young MN; Holt MV; Fandino D; Vollert CT; Singh P; Alzubi MA; Malovannaya A; Dobrolecki LE; Lewis MT; Li S; Foulds CE; Ellis MJ
Cancer Res; 2023 Oct; 83(19):3237-3251. PubMed ID: 37071495
[TBL] [Abstract] [Full Text] [Related]
20. Salivary Gland Secretory Carcinoma: Clinicopathologic and Genetic Characteristics of 215 Cases and Proposal for a Grading System.
Baněčková M; Thompson LDR; Hyrcza MD; Vaněček T; Agaimy A; Laco J; Simpson RHW; Di Palma S; Stevens TM; Brcic L; Etebarian A; Dimnik K; Majewska H; Stárek I; O'Regan E; Salviato T; Helliwell T; Horáková M; Biernat W; Onyuma T; Michal M; Leivo I; Skalova A
Am J Surg Pathol; 2023 Jun; 47(6):661-677. PubMed ID: 37070739
[TBL] [Abstract] [Full Text] [Related]
[Next]
